- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03891056
Metabolic Surgery; Gastric Bypass vs Sleeve Gastrectomy; Efects Over Type 2 DM With Bad Metabolic Control (MSO1CT) (MSO1CT)
METABOLIC SURGERY FOR PATIENTS WITH TYPE 2 DM AND GRADE I OBESITY (BMI 30-35 kg/m2) WITH BAD METABOLIC CONTROL (HbA1c > 7,5%) PROTOCOL
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Hyphotesis Laparoscopic gastric bypass is the elective technique in the face of sleeve gastrectomy to improve or heal type 2 diabetes mellitus in patientes with BMI 30-35 kg/m2.
MAIN AIM:
To compare cure rate through the improvement in glycated hemoglobin and fasting glycaemia after laparoscopic gastric bypass face to sleeve gastrectomy.
SECONDARY AIMS:
To quantify both insulin and oral hypoglycemic agents dose decrease. To measure weight loss and its maintenance during the follow-up in both techniques.
To compare postoperative complications. To compare postoperative pain. To compare follow-up complications.
Matherial and methods. Type of study: Randomized clinical trial double blind with two paralel groups.
RANDOMIZATION. Randomization will be a simple one with Epidat 4.1. A number sequence will be carried out and it will be kept in opaque closed envelopes. The envelope will be opened the operation day and the surgery technique will be decided randomly, according to the randomization sequence. The study will be blinded for patients, who will not know the surgery technique they will go on. Dieticians and Endocrinologists who will follow the patients up after the surgery neither will not know it, so differences in dietary recommendations will not appear with this masking.
Subjects of study The study will rely on patients with Diabetes Mellitus type 2 and grade I obesity with HbA1c higher than 7,5 % (BMI 30-35 kg/m2 and type 2 diabetes with bad glycemic control) detected in Endocrinology and Nutrition Department of Hospital Doctor Peset. Patients will go on bariatric surgery in General and Digestive Surgery Department of the same hospital. Patients who accomplish established inclusion criteria will be recruited until sample size is completed; a minimum 40 patients size is estimated (with a type I error of 5% and a power of 80%) and the will be randomized in two 20 people branches. Investigation will follow The World Medical Association and Declaration of Helsinki guidelines.
Definition of healing and improvement. Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits without needing oral hypoglycemic agents.
Improvement will be defined when decreasing medication doses for keeping normal fasting glycaemia and level of HbA1c under 6%.
Period of study:
The required one for fulfilling the sample. An inclusion of 40 patients in two years is expected.
Variable-gathering period The patient will be call for attending the external consultation of the Endocrinology and Nutrition Department of Hospital Doctor Peset. Each subject will carry out an initial study with nutritional status assesment, cardiovascular risk factors and comorbidities (hypertension, obstructive sleep apnea, dyslipidemia), as well as discarding secondary causes of obesity. In basal state, 2 days, 3, 6 and 12 months after the surgery, a blood test consisting of biochemical analysis, specific proteins, serum hormones, inmunological markers, full blood count and hemostasis will be made. The patient will carry out dietary intervention and follow-up in each phase of the process.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Nuria Peris Tomás, PhD
- Telefonnummer: 0034 617019132
- E-post: nuriapt27@gmail.com
Studera Kontakt Backup
- Namn: Jose Angel Diez Ares, PhD
- Telefonnummer: 0034 619702452
- E-post: jose_angel_diez_ares@hotmail.com
Studieorter
-
-
-
Valencia, Spanien, 46017
- Rekrytering
- Department of General and Digestive Surgery of the Dr. Peset Hospital
-
Kontakt:
- Nuria Peris Tomás, PhD
- Telefonnummer: 0034 617019132
- E-post: nuriapt27@gmail.com
-
Kontakt:
- Jose Angel Diez Ares, PhD
- Telefonnummer: 0034 619702452
- E-post: jose_angel_diez_ares@hotmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Both sex patients aged between 18 and 65 years old
- Class I obesity (BMI 30-35 kg/m2) with bad metabolic control (DM-2 with HbA1c > 7,5%) and non-insulin anti-diabetic treatment failure (it is necessary >10 years of known diabetes evolution time, C-peptide≥ 1 ng/ml, no insulin treatment, at least two oral hypoglycemic agents treatment);
- Patients who accomplish the follow-up protocol designed by both Surgery and Endocrinology departments
- Informed consent signed
Exclusion Criteria:
- Patients who do not accomplish the previosly described inclusion criteria; Patient's refusal to take part in the study; Patients with symptomatology of gastroesophageal reflux disease or with upper gastrointestinal series compatible with this desease.
Previous bariatric surgery
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Gastric bypass
Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Aktiv komparator: Slevee gastrectomy
Twenty patients will be randomly assigned to perform a sleeve gastrectomy
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of participans with normal glycosylated hemoglobin levels
Tidsram: 1 year after surgery
|
Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits (Hb1Ac < 6%, FBG<100mg/dl) without needing oral hypoglycemic agents.
|
1 year after surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of participants with partial remission or improvement of diabetes
Tidsram: 1 year after surgery
|
Partial remission: Subdiabetic hyperglycemia (Hb1Ac 6%-6,4%, FBG 100-125mg/dl) in the absence anti diabetic medication. Improvement: statistically significant reduction in Hb1Ac and FBG not meeting criteria for remission or decrease in anti diabetic medication requirement (by one oral agent, or 1/2 reduction in dose) |
1 year after surgery
|
Comparison of weight loss between the two techniques; bypass and sleeve.
Tidsram: 2 years after surgery
|
To measure weight loss and its maintenance during the follow-up in both techniques.
For this, the patients will be weighed in the postoperative period at month, 3, 6 12 months and then annually.
|
2 years after surgery
|
Evaluation of postoperative complications in patients undergoing bypass and slevee with Clavien-Dindo classification.
Tidsram: 1 month after surgery
|
Grade I: any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutritional also included. Grade III: Requiring surgical, endoscopic or radiological intervention. Grade IV: Life-threatening complication requiring IC/ICU management. Grade V: Death of a patient. |
1 month after surgery
|
Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.
Tidsram: 3 days postoperative
|
The postoperative pain of the patients during the first three postoperative days will be evaluated with the visual analogue scale from 0 (no pain) to 10 (unbearable pain).
|
3 days postoperative
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MSO1CT
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAvslutadDiabetes mellitus | Typ 2-diabetes mellitus | Vuxendiabetes mellitus | Icke-insulinberoende diabetes mellitus | Noninsulinberoende diabetes mellitus, typ IIFörenta staterna
-
Guang NingRekryteringTyp 2-diabetes mellitus | Typ 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Läkemedelsinducerad diabetes mellitus | Andra former av diabetes mellitusKina
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Diabetes typ 1 | Typ 1-diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinberoende | Ungdomsdiabetes | Diabetes, autoimmun | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | Diabetes mellitus, spröd | Diabetes mellitus, juvenil-debut och andra villkorFörenta staterna
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Peking Union Medical College HospitalOkändTyp 2-diabetes mellitus | Typ 1-diabetes mellitus | Graviditetsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestationsdiabetes mellitus | Diabetespatienter i perioperativ periodKina
-
Leiden University Medical CenterAndaluz Health ServiceAvslutadDiabetes mellitus | Hälsobeteende | Självförmåga | Typ 2 diabetes mellitus | Typ 1 diabetes mellitusNederländerna, Spanien
-
Meir Medical CenterAvslutadDiabetes mellitus typ 2 | Diabetes mellitus, icke-insulinberoende | Diabetes mellitus, om oral hypoglykemisk behandling | Vuxen typ diabetes mellitusIsrael
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAvslutadTyp 2-diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAvslutadTyp 1-diabetes mellitus | Diabetes mellitus, typ I | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | IDDMFörenta staterna, Australien
Kliniska prövningar på metabolic surgery
-
Myota GmbHLindus HealthAvslutadPre-diabetesStorbritannien
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of Sheffield; Nutricia UK LtdAvslutadRyggmärgsskada, akutStorbritannien
-
Arizona State UniversityAvslutad
-
Jean-Claude TardifMontreal Heart Institute; Polytechnique MontréalAvslutad
-
Royal Surrey County Hospital NHS Foundation TrustOkändÄggstockscancer | Äggledarcancer | Peritoneal cancer | Ovarial neoplasm | Ovarian Neoplasm EpitelialStorbritannien
-
University of Colorado, DenverRekryteringFörbättrad återhämtning efter operation | Gynekologisk sjukdomFörenta staterna
-
Nanjing University School of MedicineHar inte rekryterat ännu
-
ARCAGY/ GINECO GROUPRekryteringÄggstockscancer Stadium IIIC | Äggstockscancer Steg IV | Äggstockscancer Stadium IIIbFrankrike
-
University of Illinois at ChicagoHar inte rekryterat ännuProstatahyperplasi
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekrytering